Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 39.02% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 30.84% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -22.99% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 9.68% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 1,133.33% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 142.64% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 53.76% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -73.62% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -106.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 142.64% |
| Mar 31, 2026 | 143.40% |
| Dec 31, 2025 | 156.12% |
| Sep 30, 2025 | 189.65% |
| Jun 30, 2025 | 78.26% |
| Mar 31, 2025 | -30.86% |
| Dec 31, 2024 | -40.60% |
| Sep 30, 2024 | -75.47% |
| Jun 30, 2024 | -49.63% |
| Mar 31, 2024 | -6.61% |
| Dec 31, 2023 | -29.24% |
| Sep 30, 2023 | 3.53% |
| Jun 30, 2023 | -0.85% |
| Mar 31, 2023 | -22.22% |
| Dec 31, 2022 | -1.15% |
| Sep 30, 2022 | -36.65% |
| Jun 30, 2022 | 42.76% |
| Mar 31, 2022 | 3.96% |
| Dec 31, 2021 | 1.01% |
| Sep 30, 2021 | 109.87% |